[PDF][PDF] Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature
A Alhowail, R Alsikhan, M Alsaud… - Drug Design …, 2022 - Taylor & Francis
Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, is
known to have anti-inflammatory and anti-oxidant effects on the brain, and its clinical …
known to have anti-inflammatory and anti-oxidant effects on the brain, and its clinical …
Neuroprotective and anti-inflammatory effects of pioglitazone on Parkinson's disease: A comprehensive narrative review of clinical and experimental findings
Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized
by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …
by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) …
[HTML][HTML] Effects of peroxisome proliferator-activated receptor-gamma agonists on cognitive function: a systematic review and meta-analysis
H Zhong, R Geng, Y Zhang, J Ding, M Liu, S Deng… - Biomedicines, 2023 - mdpi.com
Diabetes mellitus (DM) is known to be a risk factor for dementia, especially in the elderly
population, and close associations between diabetes and Alzheimer disease (AD) have …
population, and close associations between diabetes and Alzheimer disease (AD) have …
PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus
LY Jiang, SS Tang, XY Wang, LP Liu… - CNS neuroscience & …, 2012 - Wiley Online Library
Aims: Pioglitazone, known as a peroxisome proliferator‐activated receptor γ (PPARγ)
agonist, is used to treat type 2 diabetes mellitus (T2DM). T2DM has been associated with …
agonist, is used to treat type 2 diabetes mellitus (T2DM). T2DM has been associated with …
Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease
R Gupta, LK Gupta - Pharmacology Biochemistry and Behavior, 2012 - Elsevier
Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists (thiazolidinediones)
are widely prescribed for the treatment of type-II diabetes mellitus. Recently, PPAR-γ …
are widely prescribed for the treatment of type-II diabetes mellitus. Recently, PPAR-γ …
PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson's disease
N Schintu, L Frau, M Ibba, P Caboni… - European Journal of …, 2009 - Wiley Online Library
Rosiglitazone is a commonly prescribed insulin‐sensitizing drug with a selective agonistic
activity on the peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ). PPAR‐γ can …
activity on the peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ). PPAR‐γ can …
[HTML][HTML] Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance …
QQ Yin, JJ Pei, S Xu, DZ Luo, SQ Dong, MH Sun… - PloS one, 2013 - journals.plos.org
Insulin resistance (IR) links Alzheimer's disease (AD) with oxidative damage, cholinergic
deficit, and cognitive impairment. Peroxisome proliferator-activated receptor γ (PPARγ) …
deficit, and cognitive impairment. Peroxisome proliferator-activated receptor γ (PPARγ) …
[HTML][HTML] Effects of long-term pioglitazone treatment on peripheral and central markers of aging
EM Blalock, JT Phelps, T Pancani, JL Searcy… - PloS one, 2010 - journals.plos.org
Background Thiazolidinediones (TZDs) activate peroxisome proliferator-activated receptor
gamma (PPARγ) and are used clinically to help restore peripheral insulin sensitivity in Type …
gamma (PPARγ) and are used clinically to help restore peripheral insulin sensitivity in Type …
Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a …
AR Carta, L Frau, A Pisanu, J Wardas, S Spiga… - Neuroscience, 2011 - Elsevier
Thiazolidinedione (TZD) class of peroxisome proliferator receptor gamma (PPAR-γ) agonists
display neuroprotective effects in experimental Parkinson's disease (PD) models. Neurons …
display neuroprotective effects in experimental Parkinson's disease (PD) models. Neurons …
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury
A Sauerbeck, J Gao, R Readnower, M Liu… - Experimental …, 2011 - Elsevier
Following traumatic brain injury (TBI) there is significant neuropathology which includes
mitochondrial dysfunction, loss of cortical gray matter, microglial activation, and cognitive …
mitochondrial dysfunction, loss of cortical gray matter, microglial activation, and cognitive …